Contact Us
Contact Us
Contact Us

Unlocking the Skin as a New Route for Peptide Therapeutics

InsuLife® is advancing a proprietary transdermal delivery platform designed to enable convenient, painless administration of peptide therapeutics, with lead programs in insulin and GLP-1 receptor agonists.

Our Company

Transforming Drug Delivery Through Innovation
InsuLife is a biotechnology company developing needle-free therapies using its proprietary Lipid Envelope Delivery (LED) platform. Our mission is to improve treatment convenience, patient adherence, and quality of life by enabling the transdermal delivery of peptide medicines  > Learn More

About LED

A Platform Designed for the Future of Medicine
LED is InsuLife's proprietary transdermal delivery technology designed to transport therapeutic peptides through the skin without injections. The platform is being developed to support multiple peptide-based therapies, creating opportunities across diabetes, obesity, and other chronic diseases.  > Discover the LED Technology

Our Pipeline

Advancing Multiple Needle-Free Therapies
ILS-2501 A developmental transdermal insulin product designed to eliminate the need for daily insulin injections.
ILS-2601 A developmental transdermal GLP-1 receptor agonist targeting obesity - one of the fastest-growing pharmaceutical markets.
>Explore Our Pipeline

Our Team

Science, Strategy and Commercial Expertise
Our multidisciplinary team combines extensive experience in drug development, intellectual property, corporate strategy and commercialization to advance innovative therapies from concept to market. > Learn More

Addressing Major Global Health Challenges

“Diabetes is one of the fastest growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years.”
-International Diabetes Federation
“More than half of all adults and a third of children, teenagers and young adults around the world are predicted to be overweight or obese by 2050.”
-Lancet, 2025
InsuLife® is advancing a proprietary transdermal delivery platform designed to enable convenient, painless administration of peptide therapeutics, with lead programs in insulin and GLP-1 receptor agonists.
Learn More
© Copyright 2026 - InsuLife AS, All Rights Reserved
dropuserslocationcross